Abstract:ID 99907 Poster Board 509 Radiation poses a serious threat to active-duty military personnel, causing a multitude of health problems for those who are exposed, including the potential for radiation-induced cognitive decline. Recent studies have shown that metformin–an antidiabetic drug–could attenuate the cognitive decline following radiotherapy for brain tumors. Our study tested the hypothesis that metformin prophylaxis would attenuate the central nervous system (CNS) effects of a whole-body non-lethal radiation exposure dose more representative of an exposure military personnel might encounter. Female Long-Evans rats were injected with metformin (200 mg/kg per day) for 7 days prior to exposure to gamma radiation (2 Gy; 0.6 Gy/m) using the AFRRI high level cobalt facility. At 2 days following radiation exposure, the effects of metformin prophylaxis were assessed on serum chemistry, hematological endpoints, blood hormone levels, and markers of cell proliferation and neuroinflammation in different brain regions. In a separate group of rats, a behavioral battery was assessed from 7-30 days following radiation exposure, assessing recognition and spatial memory, and anxiety-like and depressive-like behaviors. Following behavioral testing, serum chemistry, hematological endpoints, and makers of cell proliferation and neuroinflammation in different brain regions were assessed. At the 2-day time point, 2 Gy gamma radiation significantly decreased white blood cells, lymphocytes, monocytes, and reticulocytes, with no effect of metformin. Metformin did prevent the radiation-induced decrease in uric acid at this time point. Further, metformin administration appears to have prevented the radiation-induced decrease in lactate, as well, but this effect did not achieve significance. At the 30-day time point, metformin administration significantly increased recovery of reticulocytes. We found a significantly decreased Glu/Gla osteocalcin ratio at 2 days following radiation in the metformin + radiation group compared to sham control. At 30 days following radiation exposure, there was a significant effect of radiation on the Glu/Gla osteocalcin ratio, with radiation exposure resulting in a significant decrease in this ratio compared to sham control rats. This suggests that the Glu/Gla osteocalcin ratio is potentially a biomarker of radiation exposure. Rats receiving metformin prophylaxis showed faster habituation in the open field test compared to all other groups. Taken together, metformin shows potential as prophylaxis for radiation-induced changes following a non-lethal dose of gamma radiation. Intramural funds (AFR-B2-12672) from the Armed Forces Radiobiology Research Institute.

Radioprotective effect of the anti-diabetic drug metformin

Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition

Metformin as a Radiation Modifier; Implications to Normal Tissue Protection and Tumor Sensitization

Metformin Protects against Radiation-Induced Acute Effects by Limiting Senescence of Bronchial-Epithelial Cells

Radiosensitization of metformin in pancreatic cancer cells via abrogating the G2 checkpoint and inhibiting DNA damage repair

Exploring the Potential of Metformin in Mitigating Radiation-induced Gastrointestinal and Hematopoietic System Injury in Rats After Whole-body X-ray Radiation: An Experimental Study

Metformin as a Potential Countermeasure for the Central Nervous System Effects of Radiation Exposure

Metformin mitigates gastrointestinal radiotoxicity and radiosensitises P53 mutation colorectal tumours via optimising autophagy

High-dose metformin induces a low-glucose dependent genotoxic stress

Suppressive Effects of Metformin on Colorectal Adenoma Incidence and Malignant Progression

Metformin Ameliorates 2.856 GHz Microwave- Radiation-Induced Reproductive Impairments in Male Rats via Inhibition of Oxidative Stress and Apoptosis

Metformin Reduces Renal Uptake of Radiotracers and Protects Kidneys from Radiation-Induced Damage.

The effect of metformin on viability and mitochondrial status of tumor and non-tumor cell line

Metformin enhanced in vitro radiosensitivity associates with G2/M cell cycle arrest and elevated adenosine-5’-monophosphate-activated protein kinase levels in glioblastoma

Metformin Protects Against Radiation-Induced Pneumonitis and Fibrosis and Attenuates Upregulation of Dual Oxidase Genes Expression

Metformin transiently inhibits colorectal cancer cell proliferation as a result of either AMPK activation or increased ROS production

Metformin Radiosensitizing Effect on Hypoxic Oral Squamous Cell Carcinoma Cells by GAPDH and TAGLN2

Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis

Metformin ameliorates 5-fluorouracil-induced intestinal injury by inhibiting cellular senescence, inflammation, and oxidative stress

Metformin impacts the differentiation of mouse bone marrow cells into macrophages affecting tumour immunity

Metformin protects 5-Fu-induced chemotherapy oral mucositis by reducing endoplasmic reticulum stress in mice